Population Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Implanted in the Eye in Patients With Neovascular Age-Related Macular Degeneration
This article is protected by copyright. All rights reserved.PMID:37291950 | DOI:10.1002/jcph.2290 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - June 9, 2023 Category: Drugs & Pharmacology Authors: Matts K ågedal Oskar Alsk är Klas Petersson Eva Hanze Mauricio Maia Tong Lu Shweta Vakhavkar Angelica Quartino Jeffrey R Willis Jin Y Jin Katie F Maass Source Type: research
Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases
Eur J Med Chem. 2023 May 29;257:115535. doi: 10.1016/j.ejmech.2023.115535. Online ahead of print.ABSTRACTAngiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular endothelial growth factor receptor (VEGFR) is a crucial cell membrane receptor that binds to VEGF to regulate angiogenesis and maintenance. Dysregulation of VEGFR signaling can lead to several diseases, such as cancer and ocular neovascular disease, making it a crucial research area for disease treatment. Currently, anti-VE...
Source: European Journal of Medicinal Chemistry - June 7, 2023 Category: Chemistry Authors: Die Jiang Ting Xu Lei Zhong Qi Liang Yonghe Hu Wenjing Xiao Jianyou Shi Source Type: research
Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases
Eur J Med Chem. 2023 May 29;257:115535. doi: 10.1016/j.ejmech.2023.115535. Online ahead of print.ABSTRACTAngiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular endothelial growth factor receptor (VEGFR) is a crucial cell membrane receptor that binds to VEGF to regulate angiogenesis and maintenance. Dysregulation of VEGFR signaling can lead to several diseases, such as cancer and ocular neovascular disease, making it a crucial research area for disease treatment. Currently, anti-VE...
Source: European Journal of Medicinal Chemistry - June 7, 2023 Category: Chemistry Authors: Die Jiang Ting Xu Lei Zhong Qi Liang Yonghe Hu Wenjing Xiao Jianyou Shi Source Type: research
CO35 Real-World Effectiveness of Intravitreal Ranibizumab and Aflibercept for Eyes with Central Retinal Vein Occlusion: A Multi-Institutional Cohort Study in Taiwan
Intravitreal ranibizumab and aflibercept is the mainstream therapy for central retinal vein occlusion (CRVO), a common cause of vision loss in adults. However, the long-term effectiveness of changes in central retinal thickness (CRT) and visual acuity (VA) post ranibizumab and aflibercept therapy remains unclear in Taiwan. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: C. Liu, S.C. Shao Source Type: research
EE313 Utilisation of the Cost-Saving Impact of Biosimilar Switching in Ophthalmological Diseases in the NHS: A Case-Study for a Ranibizumab Biosimilar
This study aims to calculate savings generated from the switch of the reference ranibizumab molecule, to a ranibizumab biosimilar, and explore how savings could be reinvested. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Keady, I. Rickard, Q. Xin, L. Morris, M. Thomas, G. Foxon Source Type: research
EE426 A Comparison of the Cost-Saving Impact of Biosimilar Switching Policies across Canadian Provinces: A Case-Study for a Ranibizumab Biosimilar
This examined the impact of differing ophthalmology biosimilar switching policies on cost-savings for Canadian payors. The anticipated budget impact of a ranibizumab biosimilar was estimated across ten provincial drug plans. Resulting analysis identified possible opportunities for increased drug plan cost-savings associated with adopting proactive biosimilar switching policies. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Keady, N. Goyert-Stephens, Q. Xin, L. Morris, M. Thomas, G. Foxon Source Type: research
Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis
CONCLUSION: This study found that there was no difference in BCVA, CMT or adverse reactions between AFL and RAN at 6 and 12 months of follow-up, but AFL needed fewer IVIs than RAN.PMID:37226427 | DOI:10.1177/11206721231178658 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - May 25, 2023 Category: Opthalmology Authors: Haiyan Chen Xuehui Shi Wang Zhang Qianqian Han Source Type: research
Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis
ConclusionConbercept had a higher rate of primary cure in ROP patients. More RCTs are needed to compare the efficacy of conbercept and ranibizumab in treating ROP. (Source: International Journal of Clinical Pharmacy)
Source: International Journal of Clinical Pharmacy - May 19, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis
ConclusionBrolucizumab 6 mg Q12W/Q8W was comparable or superior to aflibercept 2 mg and ranibizumab 0.5 mg regimens for various visual and anatomical efficacy outcomes and discontinuation rates. (Source: Diabetes Therapy)
Source: Diabetes Therapy - May 17, 2023 Category: Endocrinology Source Type: research
Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis
ConclusionsThis meta-analysis showed that the advantages of IAI are obvious in the management of DME and PDR with poor baseline vision for long-term observation (a minimum of 12 months and up to 24 months) with both VA improvement and CST reduction. Applied IAI separately trended to be more effective than panretinal photocoagulation separately in VA improvement for PDR. More parameters should be required to assess functional and anatomic outcomes. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - May 16, 2023 Category: Endocrinology Source Type: research
Dropped nucleus postintravitreal injection with intact anterior capsule: a case report
CONCLUSION: This rare complication highlights the importance of carefully following IVI guidelines in the hands of experienced ophthalmologists and the need for meticulous supervision for ophthalmology residents because it is not a risk-free procedure.PMID:37113849 | PMC:PMC10129212 | DOI:10.1097/MS9.0000000000000345 (Source: Hand Surgery)
Source: Hand Surgery - April 28, 2023 Category: Surgery Authors: Motasem M Al-Latayfeh Reham Shehada Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Dropped nucleus postintravitreal injection with intact anterior capsule: a case report
CONCLUSION: This rare complication highlights the importance of carefully following IVI guidelines in the hands of experienced ophthalmologists and the need for meticulous supervision for ophthalmology residents because it is not a risk-free procedure.PMID:37113849 | PMC:PMC10129212 | DOI:10.1097/MS9.0000000000000345 (Source: Hand Surgery)
Source: Hand Surgery - April 28, 2023 Category: Surgery Authors: Motasem M Al-Latayfeh Reham Shehada Source Type: research
